Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Moasser

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 27, 2022
Molecular Pathways and Mechanisms of HER2 in Cancer TherapyKanwal P S Raghav, Mark M Moasser
Cell Chemical Biology|July 22, 2017
Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 PseudokinasePeter Littlefield, Mark M Moasser, Natalia Jura
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapyMarcia R Campbell, Dhara Amin, Mark M Moasser
Seminars in Cell & Developmental Biology|September 7, 2010
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeuticsDhara N Amin, Marcia R Campbell, Mark M Moasser
Cell Cycle (Georgetown, Tex.)|April 15, 2011
Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage stateDanislav S Spassov, Ching H Wong, Mark M Moasser
Molecular Cancer Therapeutics|October 7, 2015
A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified CancersDhara N Amin, Deepika Ahuja, Paul Yaswen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signalingQing-Bai She, David Solit, Andrea Basso, et al.
Cell Reports|October 11, 2018
A Dimerization Function in the Intrinsically Disordered N-Terminal Region of SrcDanislav S Spassov, Ana Ruiz-Saenz, Amit Piple, et al.
Oncotarget|October 31, 2015
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinibDhara N Amin, Ana Ruiz-Saenz, Nathaniel Gulizia, et al.
Plos One|May 12, 2011
The structural features of Trask that mediate its anti-adhesive functionsDanislav S Spassov, Deepika Ahuja, Ching Hang Wong, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 27, 2022
Molecular Pathways and Mechanisms of HER2 in Cancer TherapyKanwal P S Raghav, Mark M Moasser
Cell Chemical Biology|July 22, 2017
Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 PseudokinasePeter Littlefield, Mark M Moasser, Natalia Jura
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapyMarcia R Campbell, Dhara Amin, Mark M Moasser
Seminars in Cell & Developmental Biology|September 7, 2010
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeuticsDhara N Amin, Marcia R Campbell, Mark M Moasser
Cell Cycle (Georgetown, Tex.)|April 15, 2011
Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage stateDanislav S Spassov, Ching H Wong, Mark M Moasser
Molecular Cancer Therapeutics|October 7, 2015
A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified CancersDhara N Amin, Deepika Ahuja, Paul Yaswen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signalingQing-Bai She, David Solit, Andrea Basso, et al.
Cell Reports|October 11, 2018
A Dimerization Function in the Intrinsically Disordered N-Terminal Region of SrcDanislav S Spassov, Ana Ruiz-Saenz, Amit Piple, et al.
Oncotarget|October 31, 2015
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinibDhara N Amin, Ana Ruiz-Saenz, Nathaniel Gulizia, et al.
Plos One|May 12, 2011
The structural features of Trask that mediate its anti-adhesive functionsDanislav S Spassov, Deepika Ahuja, Ching Hang Wong, et al.
Pageof 6